Gland Pharma Ltd - GLAND PHARMA Share Price

Sector: Pharmaceuticals | ISIN: INE068V01023
₹ 1,675.10 (1.47%) icon29 Sep, 2023, 3:59:26 PM
Open
₹ 1,667.80
Prev. Close
₹ 1,650.80
Turnover(lac)
₹ 7,059.61
Day's High
₹ 1,713.00
Day's Low
₹ 1,664.35
52 Wk High
₹ 2,238.00
52 Wk Low
₹ 861.00
Book Value
₹ 494.28
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 27,589.03
P/E
35.89
EPS
46.67
Div. Yield
0.00

Gland Pharma Ltd Stock View

info icon
Edit Image
BUY
Target | 21 Aug, 2023 1,471.88 (-12.13%)

Gland Pharma Limited is an India-based generic injectable-focused company. The Company specializes in complex injectables and is engaged in the sterile injectables, oncology, and ophthalmolo... Read More

Gland Pharma Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 9/29/2023 3:59:26 PM

    ₹ 1675.1 24.30 1.47
  • Open
  • ₹ 1,667.8
  • Prev. Close
  • ₹ 1,650.8
  • Turnover(Lac.)
  • ₹ 7,060
  • Day's High
  • ₹ 1,713
  • Day's Low
  • ₹ 1,664.35
  • 52 Week's High
  • ₹ 2,238
  • 52 Week's Low
  • ₹ 861
  • Book Value
  • ₹ 494.28
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 27,589.03
  • P/E
  • 35.89
  • EPS
  • 46.67
  • Divi. Yield
  • 0

Gland Pharma Ltd Corporate Actions

18 May , 2023

12:00 AM

AGM

Announcement date: 18 May , 2023

View Details

27 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Jul , 2023

12:00 AM

28 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Mar , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

06 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

06 Jan , 2023

12:00 AM

10 Oct , 2022

12:00 AM

10 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

Gland Pharma Ltd News and Update

Image not found
  • 29 September, 2023 |
  • 8:36 PM

The deal will be carried out through a wholly-owned subsidiary called Sun Pharma (Netherlands) B.V., the company said, adding that it would "enable Sun Pharma to acquire the balance 25% stake held by the local partner."

Image not found
  • IIFL News Service |
  • 28 September, 2023 |
  • 8:34 PM
Image not found
  • IIFL News Service |
  • 27 September, 2023 |
  • 8:33 PM
Image not found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Gland Pharma Ltd SHAREHOLDING SNAPSHOT
02 October , 2023 | 04:40 AM

PROMOTER - TOTAL57.86%

Indian: 0.00%

Foreign: 57.8588%

NON-PROMOTER - TOTAL 42.14%

Institutions: 26.18%

Non-Institutions: 15.96%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Gland Pharma Ltd FINANCIALS

Gland Pharma Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Gland Pharma Ltd

  • Yiu Kwan Stanley Lau
  • Chairman & Independent Directo
  • SRINIVAS SADU
  • Managing Director & CEO
  • QIYU CHEN
  • Non-Exec & Non-Independent Dir
  • UDO JAHANNES VETTER
  • Non-Exec & Non-Independent Dir
  • C S N Murthy
  • Independent Director
  • ESSAJI GOOLAM VAHANVATI
  • Independent Director
  • Naina Lal Kidwai
  • Independent Director
  • Jia Ai (Allen) Zhang
  • Non-Exec & Non-Independent Dir
  • Yao Fang
  • Non-Exec & Non-Independent Dir

Summary

Gland Pharma Ltd was incorporated as Gland Pharma Private Limited, a private limited company under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the Company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994 and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956. The Company is primarily engaged in manufacturing injectable formulations.The company is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. The company has 8 manufacturing facilities in India, comprising four finished formulations facilities with a total of 23 production lines and three API facilities. The company sells products primarily under a business to business (B2B) model in over 60 countries as of March 31, 2022, including the United States, Europe, Canada, Australia, India and the Rest of the world. The company has a consistent compliance track record with a range of regulatory regimes across these markets. The company also have an extensive track record in complex injectables development, manufacturing and marketing and a close understanding of the related... Read More


Reports by Gland Pharma Ltd


Reports by Gland Pharma Ltd

Company FAQ

No Record Found